Pfizer Inc (PFE)

$27.06 +0.41 (1.54%)
Market Cap 151.52B
Revenue (ttm) 62.58B
Net Income (ttm) 7.77B
EPS (ttm) N/A
PE Ratio 8.32
Forward PE 9.05
Profit Margin 12.42%
Debt to Equity Ratio 0.66
Volume 34,166,000
Avg Vol 49,222,008
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 44%
Beta 0.47
Analysts Sell
Price Target $28.73

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
raticals
raticals Feb. 24 at 2:13 PM
$VKTX I find it comical $PFE is chasing another obesity asset especially China. Nothing like paying $7-10 billion for Metsera that you don’t have great confidence in I guess
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Feb. 24 at 1:57 PM
$PFE strength as they expand CHINA relationships... guess whatever it takes to elevate the share price, but odd strategic component in the current environment for sure. Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million . The U.S. drugmaker reached an agreement with Hangzhou Sciwind Biosciences for ecnoglutide, a drug recently approved by Chinese regulators to treat diabetes, according to a statement posted on WeChat on Tuesday.
0 · Reply
xCrocodileTeeth
xCrocodileTeeth Feb. 24 at 1:54 PM
Crazy call, glad you called it near bottom, i love catching them type of early plays. I would start following @TheMorningStew - Great Trader! 🔥 Greeat buys : $CLOV $RVSN $INTC $PFE
0 · Reply
Quantumup
Quantumup Feb. 24 at 1:24 PM
Oppenheimer reiterated $ORIC Outperform/$15, and said, ORIC reported fourth quarter and full year 2025 results that support what increasingly feels like a two-shots-on-goal story. $PFE $JNJ TAK AZN NVS $AVBP $BDTX Rinzimetostat continues to look competitive in mCRPC with 55% PSA50, 20% PSA90, and 59% ctDNA clearance, and has now moved into dose optimization ahead of a planned 1H26 Phase 3 start. While Pfizer's upcoming MEVPRO-1 readout will be a pivotal moment for the PRC2 class, we believe rinzi can differentiate on safety and PK. In parallel, enozertinib's exon 20 and PACC data has demonstrated systemic activity and compelling CNS control, with the Phase 3 monotherapy dose selected and combo with subcutaneous amivantamab progressing. We will be hosting ORIC management for a fireside chat during our Healthcare Conference on Wednesday, February 25th at 12:00 PM EST. Reiterate Outperform.
0 · Reply
scotttrader213
scotttrader213 Feb. 24 at 12:46 PM
$PFE Pfizer (PFE) entered a licensing agreement with China’s Sciwind Biosciences for its type 2 diabetes treatment ecnoglutide with potential payments of up to $495M if milestones are met.
0 · Reply
Quantumup
Quantumup Feb. 24 at 11:23 AM
Raymond James y'day morning reiterated $PVLA Strong Buy/$193 $TARA $PFE $NVS Raymond James said in its note to investors: Palvella (PVLA) increased its internal bar for a "decisive win" in its Phase 3 MLM program to a mean mLM-IGA score of ≥+1.0 (≥+1.5 is its upside case) from ≥+0.5. This came as a surprise to many investors given how far this bar is from the +2.4 mean CGI-C result seen in Phase 2, but our overall take is that 1) Palvella's bar, as long as other secondary endpoints/images/interviews have a similarly positive trend, is likely adequate to support approval and physician utilization, and 2) the longer study duration and data-rich expected readout will provide plenty of opportunities to convince investors of QTORIN rapamycin's treatment benefit at topline.
0 · Reply
TopazFrenzy
TopazFrenzy Feb. 24 at 9:29 AM
$NVO Decided to take a position after all ... $38.60 entry This could be like buying $PFE at $21 last year
1 · Reply
sam92
sam92 Feb. 24 at 5:30 AM
$PFE PFE gets rights to obesity drug in China. Stock ic going to ramp up and keep ramping . Pays a 6% dividend
0 · Reply
OptionGPT
OptionGPT Feb. 24 at 3:57 AM
$PFE
0 · Reply
jollygoodtime
jollygoodtime Feb. 24 at 1:54 AM
$PFE $MRNA aren't yall that got vaxed excited to learn how the origins of covid and the vaccines are in the files. don't you just love knowing you got duped by epstein and his ilk.
2 · Reply
Latest News on PFE
Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Feb 24, 2026, 7:45 AM EST - 1 hour ago

Pfizer Adds Sciwind As China Partner For New Weight Loss Drug

Pfizer in diabetes drug deal with Sciwind Biosciences

Feb 23, 2026, 10:26 PM EST - 10 hours ago

Pfizer in diabetes drug deal with Sciwind Biosciences

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

Feb 23, 2026, 3:15 PM EST - 18 hours ago

US FDA Commissioner Makary says FDA supports mRNA vaccines but US taxpayers should not bear the cost

MRK MRNA

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Feb 23, 2026, 10:00 AM EST - 23 hours ago

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Feb 20, 2026, 11:47 PM EST - 3 days ago

Pfizer: A Risky 6.3% Yield For Income-Oriented Investors

Is There 25% Downside For Pfizer Stock?

Feb 18, 2026, 12:00 PM EST - 5 days ago

Is There 25% Downside For Pfizer Stock?

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Feb 18, 2026, 11:30 AM EST - 5 days ago

Pfizer: Recovery Isn't Over, Battered Valuation Still Discounts Its Turnaround Game

Pfizer: The Rebound Looks Unsustainable

Feb 17, 2026, 5:42 PM EST - 6 days ago

Pfizer: The Rebound Looks Unsustainable

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Feb 17, 2026, 6:45 AM EST - 7 days ago

Pfizer's BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

Prices, pipelines and patent cliffs: Inside pharma's big reset

Feb 13, 2026, 6:13 AM EST - 11 days ago

Prices, pipelines and patent cliffs: Inside pharma's big reset

AMGN LLY NVO

These 32 favorite stocks signal the bull market is running on fumes

Feb 12, 2026, 8:05 AM EST - 12 days ago

These 32 favorite stocks signal the bull market is running on fumes

AAPL ABT ADBE AMGN AVGO BAC BK

Pfizer: A Great Opportunity Post Earnings

Feb 11, 2026, 6:08 PM EST - 12 days ago

Pfizer: A Great Opportunity Post Earnings

2 Urgent Sells And 2 No Brainer Dividend Buys

Feb 11, 2026, 4:06 PM EST - 12 days ago

2 Urgent Sells And 2 No Brainer Dividend Buys

ABBV AEP AMGN BMY ESS HASI HD

Is Pfizer Stock Now A Value Trap?

Feb 11, 2026, 8:56 AM EST - 13 days ago

Is Pfizer Stock Now A Value Trap?

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Feb 10, 2026, 3:20 PM EST - 13 days ago

Pfizer to collect $29 million from SEC case against Steven A. Cohen hedge fund

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Feb 8, 2026, 10:19 PM EST - 15 days ago

Pfizer: 'Hold' As Patent Cliff Looms, Along With Need For Differentiating Factor In Obesity

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

Feb 6, 2026, 2:55 PM EST - 17 days ago

Healthy Returns: Pfizer execs chart out obesity strategy after encouraging drug data

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

Feb 6, 2026, 7:25 AM EST - 18 days ago

14 Ideal 'Safer' Dividend Buys From 29 Of 69 February Graham Value All-Stars (GVAS)

ARCC ARLP CNQ EPD EQNR F FINV

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Feb 6, 2026, 6:45 AM EST - 18 days ago

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Feb 5, 2026, 7:09 PM EST - 18 days ago

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Feb 3, 2026, 3:00 PM EST - 20 days ago

Pfizer Inc. (PFE) Q4 2025 Earnings Call Transcript

Pfizer: Messy Q4 Earnings Mask An Improving Business

Feb 3, 2026, 2:02 PM EST - 20 days ago

Pfizer: Messy Q4 Earnings Mask An Improving Business

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

Feb 3, 2026, 1:27 PM EST - 20 days ago

Obesity stocks slump on Novo's underwhelming 2026 sales forecast

ALT AMGN GPCR LLY NVO VKTX

Silver Surges Over 15%; Pfizer Earnings Top Views

Feb 3, 2026, 12:00 PM EST - 20 days ago

Silver Surges Over 15%; Pfizer Earnings Top Views

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Feb 3, 2026, 11:56 AM EST - 20 days ago

Pfizer Q4 Earnings Review: This Classic Value Trap Remains As Tempting As Ever

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

Feb 3, 2026, 11:17 AM EST - 20 days ago

Pfizer, Merck report Q4 results: Citi's Geoff Meacham on key takeaways

MRK

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Feb 3, 2026, 10:15 AM EST - 20 days ago

Pfizer beats quarterly estimates despite Covid product decline - reaffirms modest outlook

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Feb 3, 2026, 8:50 AM EST - 21 days ago

Pfizer's Newly Acquired Drug Shows Weight Loss Of Just Around 13%, Stock Drops

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Feb 3, 2026, 8:17 AM EST - 21 days ago

Pfizer maps post-Covid reset with obesity trials and deep cost cuts

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Feb 3, 2026, 7:28 AM EST - 21 days ago

Pfizer says once-a-month weight-loss drug works as it forecasts profit decline

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Feb 3, 2026, 7:21 AM EST - 21 days ago

Pfizer Sales Fall on Continued Lower Covid-19 Drug Demand

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Feb 3, 2026, 7:18 AM EST - 21 days ago

Pfizer says obesity injection shows promise as monthly treatment in mid-stage trial

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Feb 3, 2026, 7:02 AM EST - 21 days ago

Pfizer Stock Falls After Solid Earnings. What's Troubling Wall Street.

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Feb 3, 2026, 6:57 AM EST - 21 days ago

Pfizer beats quarterly estimates despite Covid product decline, reaffirms modest outlook

Pfizer beats fourth-quarter profit estimates on strong drug demand

Feb 3, 2026, 6:50 AM EST - 21 days ago

Pfizer beats fourth-quarter profit estimates on strong drug demand

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Feb 3, 2026, 6:45 AM EST - 21 days ago

Pfizer's experimental drug shows up to 12.3% weight loss in mid-stage trial

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Feb 3, 2026, 6:45 AM EST - 21 days ago

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

Feb 3, 2026, 6:40 AM EST - 21 days ago

Pfizer's Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

Feb 2, 2026, 8:42 AM EST - 22 days ago

UK industry body says Sanofi in breach over RSV therapy claims against Pfizer

SNY

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Feb 2, 2026, 1:01 AM EST - 22 days ago

Pfizer Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

Jan 31, 2026, 3:47 AM EST - 24 days ago

5 'Safer' Dividend Buys In Barron's 23 Better January Bets Than T-Bill

BBY CAG EQR FRT KEY LYB MAA

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Jan 30, 2026, 10:31 AM EST - 24 days ago

Pfizer: Buyer Beware, The Risk Outweighs The Reward

Why Dividend Stocks Are Essential For What Comes Next

Jan 30, 2026, 7:30 AM EST - 25 days ago

Why Dividend Stocks Are Essential For What Comes Next

AM CAG EPD ET KMI LLY MPLX

Pfizer: A High-Yield Pharma At A Turning Point

Jan 29, 2026, 9:00 AM EST - 26 days ago

Pfizer: A High-Yield Pharma At A Turning Point

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

Jan 27, 2026, 4:52 PM EST - 27 days ago

US Medicare names Eli Lilly, Pfizer and AbbVie drugs for next Medicare price talks

ABBV LLY

Pfizer vs. Merck Stock And JNJ

Jan 27, 2026, 7:40 AM EST - 4 weeks ago

Pfizer vs. Merck Stock And JNJ

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Jan 27, 2026, 6:02 AM EST - 4 weeks ago

Pfizer: The Great Healthcare Plan Does Not Change My Bullish Stance

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

Jan 23, 2026, 10:33 AM EST - 4 weeks ago

Pfizer: Expect Another Double Beating For Q1 (Earnings Preview)

December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs

Jan 23, 2026, 9:54 AM EST - 4 weeks ago

December Readers ID'd 9 Ideal 'Safer' Dividends In 40 Dogs

AGNC AGNCP ARLP ECC EFC ET FBRT

Pfizer CEO Albert Bourla: U.S. drug prices are coming down

Jan 20, 2026, 12:34 PM EST - 4 weeks ago

Pfizer CEO Albert Bourla: U.S. drug prices are coming down

raticals
raticals Feb. 24 at 2:13 PM
$VKTX I find it comical $PFE is chasing another obesity asset especially China. Nothing like paying $7-10 billion for Metsera that you don’t have great confidence in I guess
0 · Reply
STOCKPICKERTRADER
STOCKPICKERTRADER Feb. 24 at 1:57 PM
$PFE strength as they expand CHINA relationships... guess whatever it takes to elevate the share price, but odd strategic component in the current environment for sure. Pfizer has acquired exclusive rights to commercialize an obesity therapy in China in a deal worth up to $495 million . The U.S. drugmaker reached an agreement with Hangzhou Sciwind Biosciences for ecnoglutide, a drug recently approved by Chinese regulators to treat diabetes, according to a statement posted on WeChat on Tuesday.
0 · Reply
xCrocodileTeeth
xCrocodileTeeth Feb. 24 at 1:54 PM
Crazy call, glad you called it near bottom, i love catching them type of early plays. I would start following @TheMorningStew - Great Trader! 🔥 Greeat buys : $CLOV $RVSN $INTC $PFE
0 · Reply
Quantumup
Quantumup Feb. 24 at 1:24 PM
Oppenheimer reiterated $ORIC Outperform/$15, and said, ORIC reported fourth quarter and full year 2025 results that support what increasingly feels like a two-shots-on-goal story. $PFE $JNJ TAK AZN NVS $AVBP $BDTX Rinzimetostat continues to look competitive in mCRPC with 55% PSA50, 20% PSA90, and 59% ctDNA clearance, and has now moved into dose optimization ahead of a planned 1H26 Phase 3 start. While Pfizer's upcoming MEVPRO-1 readout will be a pivotal moment for the PRC2 class, we believe rinzi can differentiate on safety and PK. In parallel, enozertinib's exon 20 and PACC data has demonstrated systemic activity and compelling CNS control, with the Phase 3 monotherapy dose selected and combo with subcutaneous amivantamab progressing. We will be hosting ORIC management for a fireside chat during our Healthcare Conference on Wednesday, February 25th at 12:00 PM EST. Reiterate Outperform.
0 · Reply
scotttrader213
scotttrader213 Feb. 24 at 12:46 PM
$PFE Pfizer (PFE) entered a licensing agreement with China’s Sciwind Biosciences for its type 2 diabetes treatment ecnoglutide with potential payments of up to $495M if milestones are met.
0 · Reply
Quantumup
Quantumup Feb. 24 at 11:23 AM
Raymond James y'day morning reiterated $PVLA Strong Buy/$193 $TARA $PFE $NVS Raymond James said in its note to investors: Palvella (PVLA) increased its internal bar for a "decisive win" in its Phase 3 MLM program to a mean mLM-IGA score of ≥+1.0 (≥+1.5 is its upside case) from ≥+0.5. This came as a surprise to many investors given how far this bar is from the +2.4 mean CGI-C result seen in Phase 2, but our overall take is that 1) Palvella's bar, as long as other secondary endpoints/images/interviews have a similarly positive trend, is likely adequate to support approval and physician utilization, and 2) the longer study duration and data-rich expected readout will provide plenty of opportunities to convince investors of QTORIN rapamycin's treatment benefit at topline.
0 · Reply
TopazFrenzy
TopazFrenzy Feb. 24 at 9:29 AM
$NVO Decided to take a position after all ... $38.60 entry This could be like buying $PFE at $21 last year
1 · Reply
sam92
sam92 Feb. 24 at 5:30 AM
$PFE PFE gets rights to obesity drug in China. Stock ic going to ramp up and keep ramping . Pays a 6% dividend
0 · Reply
OptionGPT
OptionGPT Feb. 24 at 3:57 AM
$PFE
0 · Reply
jollygoodtime
jollygoodtime Feb. 24 at 1:54 AM
$PFE $MRNA aren't yall that got vaxed excited to learn how the origins of covid and the vaccines are in the files. don't you just love knowing you got duped by epstein and his ilk.
2 · Reply
traderheadnyc
traderheadnyc Feb. 24 at 1:52 AM
$PFE got myself some June contracts today already in money :)
0 · Reply
cb5000calls
cb5000calls Feb. 24 at 1:28 AM
$SLS @Love_To_Learn are we waiting on $MRK $ABBV or $PFE to light the fuse here and trigger the #SuperNova to triple digit PT. We all know that all three desperately need to make a move soon or their patents are in deep trouble. GPS is the next paradigm shift in cancer treatement, the WT1 market is too big for SLS to handle, buyout is the only option.
2 · Reply
DragonAlgo
DragonAlgo Feb. 23 at 11:29 PM
🐉 $PFE CALL — DragonAlgo® Signal Contract: PFE CALL Expiry: 2026-02-27 | Strike: $27.00 | Type: CALL Option Plan (premium): Entry: $0.33 Stop: $0.23 TP1: $0.42 TP2: $0.55 TP3: $0.78 🔗 https://dragonalgo.com
0 · Reply
doubleuptwice
doubleuptwice Feb. 23 at 10:49 PM
$PFE confirmed this. Now let’s see the timeframe to clear 27.50 and hold then I can update
1 · Reply
TechTraderGrok
TechTraderGrok Feb. 23 at 9:31 PM
Sold $PFE at $27.04 (+7.5%). From Grok: "Exit long on PFE as MACD bearish crossover signals weakening momentum amid overbought RSI and resistance at $27.99, despite recent uptrend and positive oncology pipeline; next earnings May 4, 2026." https://www.techtrader.ai/grokwall/?post=16589&utm_source=dlvr.it&utm_medium=stocktwits
0 · Reply
Jack90
Jack90 Feb. 23 at 9:20 PM
$HIMS great earnings, probably $PFE take over at $10 Billion
0 · Reply
keroburner
keroburner Feb. 23 at 9:09 PM
$PFE Good day
0 · Reply
scotttrader213
scotttrader213 Feb. 23 at 8:44 PM
$PFE holding steady, towards 30.00
1 · Reply
jogabonito84
jogabonito84 Feb. 23 at 7:56 PM
$IBRX $ONC $MRK $PFE $TSLA Buying IBRX under $10, feels like when I bought Apple in 2007 when the iPhone just came out. Anktiva and bladder cancer are just the beginning of a new paradigm in cancer treatment
0 · Reply
Sb2001
Sb2001 Feb. 23 at 7:28 PM
$PFE is it trying to form a 26.50 floor?
0 · Reply
Willieberich
Willieberich Feb. 23 at 6:35 PM
$PFE I don't know about you guys .pfe and khc are my greenest in my portfolio. I'll stay with both .good luck people .to those who don't like boring stocks .how do you like pfe now? Know what you own...
1 · Reply
VeryContent
VeryContent Feb. 23 at 6:06 PM
$PFE life raft investment here
1 · Reply